Cancer Outpatients Research Articles

1280P Validation of HAprog, an app for advanced cancer outpatient prognostication in routine practice

HAprog is a freely and user-friendly app for prognostication of advanced cancer outpatients. It is a computational transcription of two prognostic models: a ‘full version' composed of 6 parameters: sex, locoregional disease, sites of metastasis, ECOG-PS, WBC and albumin; and a 'clinical version' adding 'antineoplastic treatment' and without laboratory variables. The prognostic predictions are expressed in probability of being alive (in 30, 90 and 180 days) and expected scenarios (days).

Willingness, preferences, barriers, and facilitators of a multimodal supportive care intervention including exercise, nutritional and psychological approach in patients with cancer: a cross-sectional study

PurposeSupportive care, including exercise, nutritional and psychological support, is becoming increasingly important in cancer given their impact on ‘patients’ quality and quantity of life. The purpose of this study was to explore willingness, preferences barriers and facilitators for a multimodal intervention in patients with cancer.MethodsAn anonymous questionnaire was proposed on randomly selected days to the patients visiting the cancer outpatients’ facilities at the Oncology Unit of the University Hospital of Verona. The questionnaire investigated willingness, preferences, barriers, and facilitators associated with participation in a multimodal program designed for patients with cancer. Exercise level was estimated using two open questions, nutritional risk was identified using the Nutritional Risk Screening 2002, while distress was evaluated with the Distress Thermometer.ResultsBased on 324 participants, 65% were interested in starting a multimodal intervention. Patients declared to prefer to receive instructions from dedicated experts, with a face-to-face approach, and during the anticancer treatment. Treatment-related side effects were the major obstacles for a multimodal program, while the availability of a specialized staff as exercise kinesiologists, dietitians, and psycho-oncologists was found to be an important facilitator for increasing ‘patients’ participation.ConclusionPatients patients with cancer are interested in participating in a multimodal supportive care program specifically designed for them. Information from this study may help to design a tailored multimodal intervention for patients with cancer.

Mild forms of thrombotic microangiopathy in patients with advanced pancreatic cancer receiving gemcitabine and nab-paclitaxel.

Thrombotic microangiopathy (TMA) is an uncommon complication that may occur in cancer patients usually as an expression of cancer-associated coagulopathy or due to drug-related toxicity. The clinical spectrum of TMA may vary from an incidental laboratory finding in cancer outpatients to potentially severe life-threatening clinical forms with organ involvement requiring prompt recognition and multidisciplinary evaluation. We present the clinical characteristics and outcomes of four patients with advanced pancreatic cancer with acute non-immune intravascular haemolysis compatible with microangiopathic acute haemolytic anaemia associated with mild thrombocytopenia during long-term gemcitabine and nab-paclitaxel treatment. Abnormal blood parameters (all four cases) and renal involvement (one case) were reversed with a conservative approach and chemotherapy discontinuation. One patient required a short hospitalization while the other three were managed as outpatients. The rapid reversibility of the blood abnormalities supported gemcitabine dose-related toxicity as the most likely aetiologic mechanism and demonstrates the current challenges in daily long-term cancer survivor care. Clinicians must take into account TMA in the differential diagnosis of acute anaemia with or without thrombocytopenia and organ damage, since adequate recognition and early treatment discontinuation allow effective outpatient management and favourable patient outcomes.

Cross-sectional Census Survey of Patients With Cancer who Received a Pharmacist Consultation in a Pharmacist Led Anti-cancer Clinic

Pharmacists have a critical consulting role in patients undergoing oral antineoplastic drug therapy to ensure harm minimisation. Studies exploring the benefits of pharmacists in this role are limited. This study evaluated patient perceptions, experiences and overall satisfaction with clinical pharmacist consultations in patients treated with oral antineoplastic drugs. Data on 160 patients initiated on oral antineoplastic drugs between January 2019 and February 2021 were collected retrospectively from an outpatient Comprehensive Cancer Centre of a quaternary hospital in Western Australia (demographics, cancer type, oral antineoplastic drugs prescribed). In addition, patients were mailed a hard copy questionnaire in March 2021 to assess their satisfaction with pharmacist consultations in the pharmacist clinic, using a 5-point Likert scale. The statements included perceptions of the patient’s understanding, medication adherence, experiences and overall satisfaction with the clinical pharmacist consultation. There were 76 (47.5%) completed questionnaires returned (52.6% female; average age was 63.2 ± 13.9 years). The majority of patients were satisfied with the service offered by the clinical pharmacist (73/76; 96.1%), perceived that clinical pharmacists provided an important service in outpatient cancer care (71/76; 93.4%) and improved their understanding of the use of oral antineoplastic drugs and side-effect management (48/74; 64.9%). Patients’ perceived understanding of their medication regimen and additional health services available improved after pharmacist counselling. The patients also reported overall satisfaction with the service provided by the clinical pharmacist and found it beneficial to their care. The study supports the expanding role of the clinical pharmacist in an outpatient cancer centre.

Community-based outpatient rehabilitation for the treatment of breast cancer-related upper extremity disability: an evaluation of practice-based evidence.

To evaluate the impact and acceptability of outpatient physical or occupational therapy (PT/OT) for breast cancer survivors (BCS) with varying levels of upper extremity disability (UED). We retrospectively extracted patient and therapy characteristics, UED measured by quick-disabilities of the arm, shoulder and hand (QuickDASH, 0-100 pts.), and patient-rated acceptability (1-item, 0-10 pts) from rehabilitation charts of BCS who completed cancer-specializedPT/OTprovided by a single national institution in 2019. We summarized characteristics and acceptability using descriptive statistics, then used established parameters to group BCS by baselineUED severity: high- (QuickDASH > 31.5), moderate- (QuickDASH = 18.5-31.5), or low-UED (QuickDASH = 13-18.5). To evaluate within-group pre-to-post QuickDASH change, we used paired samples t test (p < 0.01), then calculated the proportion who achieved the minimally clinical important difference (MCID, 15.9 points). To compare between-groups difference in QuickDASH improvement, we used Kruskal-Wallis test and Chi-squared test. Patients (N = 417) were 59.89 ± 12.06years old, 99% female, andattended approximately 10 PT/OT sessions (IQR = 6.0-16.0). Most had high baselineUED (62%), followed by moderate (25%) or lowUED (13%). For each severity group, mean pre-to-post changein QuickDASH was significant: high-UED (M∆ = 25.13 ± 20.33, d = 1.24, p < 0.01), moderate-UED (M∆ = 11.36 ± 11.9, d = 0.95, p < 0.01), and low-UED (M∆ = 4.84 ± 9.15, d = 0.53, p < 0.01). Most with high UED achieved the MCID (n = 176, 68.2%).In the moderate- and low-UED groups44% (n = 46) and 4% (n = 2) achieved the MCID, respectively. Acceptability was high (n = 167, Median = 10). Outpatient cancer rehabilitation is associated with significant improvement in UED for BCS and was acceptable to patientsregardless of UED severity at baseline.

Increasing Trends of Polypharmacy and Potentially Inappropriate Medication Use in Older Lung Cancer Patients in China: A Repeated Cross-Sectional Study.

Objectives: Polypharmacy and potentially inappropriate medication (PIM) use are frequent in older lung cancer patients. This study aimed to examine the trends of polypharmacy and PIM use and explore risk factors for PIM use based on the 2019 Beers criteria in older Chinese lung cancer outpatients with multimorbidity. Methods: A repeated cross-sectional study was conducted using electronic medical data consisting of the prescriptions of older lung cancer outpatients in China from January 2016 to December 2018. Polypharmacy was defined as the use of five or more medications. The 2019 Beers criteria were used to evaluate the PIM use of older cancer outpatients (age ≥65 years), and multivariate logistic regression was used to identify the risk factors for PIM use. Results: A total of 3,286 older lung cancer outpatients and their prescriptions were included in the study. The prevalence of polypharmacy was 14.27% in 2016, 16.55% in 2017, and 18.04% in 2018. The prevalence of PIM use, according to the 2019 Beers criteria, was 31.94% in 2016, 35.78% in 2017, and 42.67% in 2018. The two most frequently used PIMs in older lung cancer outpatients were estazolam and tramadol. The logistic regression demonstrated that age 75 to 79, polypharmacy, irrational use of drugs, and lung cancer accompanied by sleep disorders, anxiety or depression, or pain were positively associated with PIM use in older lung cancer outpatients. Conclusion: The prevalence of polypharmacy and PIM use in older lung cancer outpatients with multimorbidity was high in China, and polypharmacy and PIM use increased over time. Further research on interventions rationing PIM use in the older lung cancer patient population is needed.

Performance of Malnutrition Universal Screening Tool and Patient-Generated Global Subjective Assessment in screening for cancer-related malnutrition in Nairobi, Kenya

Background: Malnutrition is a common feature among oncology patients. It is responsible for poor response and tolerance to anticancer therapy, increased morbidity, and mortality. More than half of malnourished cancer patients remain undetected owing to lack of effective screening. Body mass index is the main indicator for assessing malnutrition in Kenyan public hospitals. However, it underestimates weight loss in patients with chronic illnesses. The Malnutrition Universal Screening Tool and Patient-Generated Subjective Global Assessment have been widely used in research and clinical practice and have both reported good validity and reliability. However, their diagnostic evaluation has not been performed in Kenya. Methods: A cross-sectional study was conducted among 138 and 76 cancer outpatients from Kenyatta National Hospital and Texas cancer treatment centres, respectively. Participants had a confirmed disease, stage 1-4 cancer, and aged 18 years and above. They were screened for malnutrition using both Malnutrition Universal Screening Tool and Patient Generated-Subjective Global Assessment. A separate study questionnaire was utilized to gather participant’s socio-demographic and clinical characteristics. A Bayesian latent class modelling framework was employed to infer the tests’ estimates based on participants ‘cumulative scores from the two tests. Results: The cut-off value of ≥ 1 and ≥ 4 gave the best combination of sensitivity and specificity of Malnutrition Universal Screening Tool and Patient Generated-Subjective Global Assessment. Both tests yielded statistically similar sensitivities and specificities. Predictive values were comparable between the tests and across the two populations. The posterior median true prevalences of malnutrition were high (˃ 54%) and numerically similar between the studied populations. Conclusions: The performance of both tests among patients with cancer is similar. Healthcare workers are therefore at liberty to use either of them to inform treatment. Given the high true prevalence of cancer-related malnutrition, routine screening is critical and should be included as part of cancer care.

Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents.

Our objectives were to analyze the use of complementary and alternative medicine (CAM) in cancer patients and to describe the incidence and characteristics of interactions between CAM and antineoplastic agents. We performed an observational study in cancer outpatients at a university hospital. Variables were collected through a 22-item questionnaire. Potential interactions between CAM and antineoplastic agents were analyzed using the Lexicomp®, the About Herbs®, and the summary of product characteristics. Mechanism of action, reliability, and the potential clinical effect of interactions were analyzed. The study population comprised 937 patients, of whom 65% used CAM (70.6% herbal products, 25.8% dietary supplements, and 3.6% homeopathy). Female sex, younger age, and breast cancer were associated with more frequent use of CAM. The primary source of information about CAM was friends and family (43.5%). A total of 335 (57.1%) patients did not tell their doctor that they took CAM. The five most common CAM were chamomile, green tea, pennyroyal mint, linden, and rooibos. At least one interaction between CAM and antineoplastic agents was reported by 65.0% of CAM users (33.9% of all patients). Depending on the mechanism of action, 80% of CAM diminished the metabolism of the antineoplastic agents. Our results reveal a high incidence of interactions between CAM and antineoplastic agents. The most frequent CAM were herbal products. Family and friends were the primary sources of information that led patients to start taking CAM, and more than half of the patients did not tell their doctor that they were taking CAM.

Responsiveness and interpretation of the PROMIS Cancer Function Brief 3D Profile.

BackgroundMeasuring function with valid and responsive tools in patients with cancer is essential for driving clinical decision‐making and for the end points of clinical trials. Current patient‐reported outcome measurements of function fall short for many reasons. This study evaluates the responsiveness of the Patient‐Reported Outcomes Measurement Information System (PROMIS) Cancer Function Brief 3D Profile, a novel measure of function across multiple domains.MethodsTwo hundred nine participants across five geographically distinct tertiary care centers completed the assessment and pain rating at two outpatient cancer rehabilitation clinic visits. Patients and providers completed a global rating of change measure at the second visit to indicate whether the patient was improving or worsening in function. Multiple response indices and linear models measured whether the measure was responsive to self‐reported and clinician‐rated changes over time. Correlations between changes in function and changes in anchors (pain rating and performance status) were also calculated.ResultsFunction as measured by the PROMIS Cancer Function Brief 3D Profile changed appropriately as both patients and clinicians rated change. Small to moderate effect sizes supported the tool's responsiveness. Function was moderately correlated with pain and more strongly correlated with performance status, and changes in function corresponded with changes in anchor variables. No floor/ceiling effect was found.ConclusionsThe PROMIS Cancer Function Brief 3D Profile is sensitive to changes over time in patients with cancer. The measure may be useful in clinical practice and as an end point in clinical trials.Lay summary We gave patients a questionnaire by which they told their physicians how well they were functioning, including how fatigued they were.This study tested that questionnaire to see whether the scores would change if patients got better or worse.

Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art.

Cancer and COVID-19 are both well-established risk factors predisposing to thrombosis. Both disease entities are correlated with increased incidence of venous thrombotic events through multifaceted pathogenic mechanisms involving the interaction of cancer cells or SARS-CoV2 on the one hand and the coagulation system and endothelial cells on the other hand. Thromboprophylaxis is recommended for hospitalized patients with active cancer and high-risk outpatients with cancer receiving anticancer treatment. Universal thromboprophylaxis with a high prophylactic dose of low molecular weight heparins (LMWH) or therapeutic dose in select patients, is currentlyindicated for hospitalized patients with COVID-19. Also, prophylactic anticoagulation is recommended for outpatients with COVID-19 at high risk for thrombosis or disease worsening. However, whether there is an additive risk of thrombosis when a patient with cancer is infected with SARS-CoV2 remains unclear In the current review, we summarize and critically discuss the literature regarding the epidemiology of thrombotic events in patients with cancer and concomitant COVID-19, the thrombotic risk assessment, and the recommendations on thromboprophylaxis for this subgroup of patients. Current data do not support an additive thrombotic risk for patients with cancer and COVID-19. Of note, patients with cancer have less access to intensive care unit care, a setting associated with high thrombotic risk. Based on current evidence, patients with cancer and COVID-19 should be assessed with well-established risk assessment models for medically ill patients and receive thromboprophylaxis, preferentially with LMWH, according to existing recommendations. Prospective trials on well-characterized populations do not exist.

O15-4 Use of virtual reality for management of anxiety and depression among chemotherapy-naive Filipino breast cancer patients

This study assessed the efficacy of immersive virtual reality (VR) as an adjunct in the management of treatment-related anxiety and depression among Filipino breast cancer outpatients undergoing chemotherapy at the University of the Philippines - Philippine General Hospital Cancer Institute.

Community-based outpatient cancer rehabilitation services for women with gynecologic cancer: acceptability and impact on patient-reported outcomes.

Women with gynecologic cancers often experience functional impairments impacting quality of life. Physical and occupational therapy (PT/OT) treat functional impairment; however, the acceptability and impact of these services for women with gynecologic cancer are unknown. We reviewed rehabilitation charts of women with gynecologic cancer who received PT/OT (i.e., patients) in 2019 and completed patient-reported outcome measures (PROMs) selected by their therapist at intake (pre) and discharge (post). We calculated descriptive statistics for patient, rehabilitation, and acceptability (0-10) data. For PROM data, we used paired samples t-tests to evaluate pre-post change, and then calculated effect size (Hedge's g) and the proportion who achieved a minimal detectable change (MDC). PT/OT patients (N = 84) were 64.63 ± 11.04years old with predominant diagnoses of ovarian (41.7%) or endometrial (32.1%) cancer. They attended a median of 13 sessions (IQR = 8.0-19.0). Sessions were predominantly PT (86%) vs. OT (14%). Median acceptability was 10 (IQR = 9.8-10.0). Pre-post improvement was observed for each of the 17 PROMs used by therapists. Significant improvement (p < .05) was observed for four PROMs: the Patient-Specific Functional Scale (M∆ = 2.93 ± 2.31, g = 1.47, 71% achieved MDC), the Lower Extremity Functional Scale (M∆ = 12.88 ± 12.31, g = 0.61, 60% achieved MDC), the Lymphedema Life Impact Scale (M∆ = 20.50 ± 20.61, g = 1.18, 58% achieved MDC), and the Modified Fatigue Impact Scale (M∆ = 6.55 ± 9.69, g = 0.33, 7% achieved MDC). PT/OT was acceptable and improved patient-reported outcomes for women with gynecologic cancers. Future research is needed to establish gynecologic-specific guidelines for referral and PT/OT practice.

Correlates of Fear of Cancer Progression during COVID-19 in Romania

Objectives. Fear of cancer progression (FoP) is one of patients’ greatest concerns and one of the most reported unmet needs. Higher levels of FoP can negatively impact a patient’s quality of life, impairing physical, emotional, social and functional well-being. The Romanian health-care system has difficulties in offering qualitative psychosocial assistance for cancer outpatients. Due to their specific implications, the COVID-19 pandemic restrictions might further affect FoP, therefore our objective was to investigate correlates of FoP in cancer outpatients during the COVID-19 pandemic in Romania. Material and methods. The study investigated correlates of FoP in 330 Romanian cancer outpatients assessed during 2021. T-tests, Multivariate General Linear Models and Hierarchical Regression Models were conducted in order to assess the relationship between variables. Outcomes. Results showed differences in the assessed variables depending on gender (women had scores significantly higher than men regarding FoP and illness intrusiveness) and marital status. Moreover, using a hierarchical regression model, we identified three statistically significant predictors of FoP: gender, illness intrusiveness regarding relationships and anxiety, together explaining 38.2% of the variance in global FoP scores. Anxiety was the most important predictor of FoP, explaining 21.3% of the variance in the FoP scores, 5 times more than gender and almost 2 times more than illness intrusiveness in interpersonal relationships. Conclusions. Cancer is a complex experience, impacted by both socio-demographic variables such as gender and marital status, as well as psychological variables such as anxiety and fear of disease progression. Individualized psychosocial-care should be recognized as essential, and personalized interventions should be integrated into the patient's treatment plan.

Remote monitoring of cancer patients during the Covid-19 pandemic – an interview study of nurses’ and physicians’ experiences

BackgroundDue to the Covid-19 pandemic, remote monitoring of patients outside hospitals rapidly increased. Previous studies show that healthcare professionals’ competence in digitalization needs to be improved. Little is known about how Covid-19 has affected the use of remote monitoring of cancer patients. The purpose of the study was therefore to explore healthcare personnels’ experiences with remote monitoring of cancer patients during the Covid-19 pandemic. MethodsThe study had an explorative and descriptive design using semi-structured individual interviews for data collection. Data was analyzed by content analysis.ResultsA total of ten healthcare personnel working in the cancer department and out-patient cancer clinic in the hospital participated; four physicians and six registered nurses. Two categories and four subcategories were identified: 1) «Maintaining personalized healthcare services» comprising the subcategories a) «Adjusting services to patients’ health condition» and b) «Ensuring continuity»; and 2) «A supplement, but not a replacement» comprising the subcategories a) «Impact on interpersonal relations» and b) «The importance of clinical assessment».ConclusionsThis study indicates that remote monitoring through telephone was preferred by both healthcare personnel and patients. The nurses and physicians experienced a more frequent contact with their patients, but emphasized the importance of physical meetings for building relationship, and for thorough clinical examination. Our findings indicate a need to facilitate a work environment where healthcare personnel can be fast learners in using digital tools to provide best possible healthcare quality. Moreover, it is imperative to develop a workplace suitable for the use of digital technology for remote monitoring, and to provide digital tools that is easy to use for both healthcare personnel and patients.

Interprofessional collaboration in the breast cancer unit: how do healthcare workers see it?

BackgroundInterprofessional collaboration has an important role in health care for breast cancer patients who are undergoing treatment at the hospital. Interprofessional collaboration has been reported to provide significant benefits for patients. However, qualitative research on interprofessional collaboration in the breast cancer department is rarely done, therefore, a study was conducted to determine the perception of health practitioners about interprofessional collaboration in the breast care unit at a referral centre hospital in West Java, Indonesia.MethodsA qualitative study was carried out using in-depth interviews and focus group discussions (FGDs) with 15 healthcare personnel using total sampling. Participants were chosen among healthcare professionals who treat and in charge for outpatient breast cancer, but were not resident physicians. The FGD approach was used for nurses and pharmacists, and interviews were used for oncologists. The audio recordings of all interviews and FGDs were transcribed verbatim and evaluated using thematic analysis.ResultThe findings were categorized into two categories to obtain health care workers' perspectives on interprofessional collaboration: (1) impediment factors: personality, lack of leadership, seniority, healthcare workers with double positions, the need for a clinical meeting, hospital bureaucracy, national health insurance implementation, issues with patients, hospital infrastructure, and evaluation and synchronisation; (2) existing supportive elements: effective cooperation, effective communication, clear job description, interpersonal relationships, Standard Operational Procedure (SOP) for cancer therapy, legality for inter-discipline cancer team, professional responsibility, integrated clinical pathway, patient centred care, and comprehensive health services.ConclusionsInterprofessional collaboration was seen positively by the respondents. However, there are several hurdles that must be overcome to apply interprofessional collaboration works effectively. The findings of this study can be used to build interprofessional collaborations targeted at enhancing quality health care in breast cancer units.

Awareness and use of psychosocial care among cancer patients and their relatives—a comparison of people with and without a migration background in Germany

PurposeWe examined how migration background is associated with awareness and usage of psycho-oncology services.MethodsOncologists in community-based practices and outpatient clinics asked their patients and their relatives to complete a questionnaire. Migrants were purposely over-sampled. The questionnaire was provided in Arabic, English, Farsi, French, German, Hindi, Kurdish, Pashto, Russian, Somali, Turkish, Urdu, and Vietnamese.ResultsFrom 9 collaborators, 177 participants were enrolled (130 with and 47 without migration background). The existence of outpatient cancer counselling centres was known to 38% of the participants without and 32% with migration background, self-help groups to 32 vs. 12%, and psychotherapy to 43 vs. 25%. Respondents from the Near and Middle East were less likely to know about psychotherapy (odds ratio (OR) 0.1, p = 0.01); those from the Commonwealth of the Independent States or former Yugoslavia were less often informed about self-help groups (OR 0.1, p = 0.06). Migrants retrieved information less frequently from the internet than non-migrants (10 vs. 25%). At least one service had been used by 27% of migrants and 42% of non-migrants (OR 0.5, p = 0.06). After adjusting for gender, age, education, and patient-relative status, there was no evidence for an association between migration background and service use.ConclusionsMigrants should be better informed about psychotherapy and self-help groups, in particular the ones coming from the Near or Middle East and the Commonwealth of the Independent States or former Yugoslavia.The under-use of psychosocial services can largely be explained by confounding factors. Therefore, these factors must always be taken into account when analysing the use of psychosocial services in the aforementioned populations.

Cancer Patients' Experiences with Telehealth before and during the COVID-19 Pandemic in British Columbia.

Background: Patients have had their cancer care either postponed or changed to telehealth visits to reduce exposure to COVID-19. However, it is unclear how these changes may have affected their experiences. We aim to identify patient characteristics that affect telehealth experiences and evaluate their preferences for using telehealth in the future. Methods: Patients who completed the Outpatient Cancer Care (OCC) Patient Experience Survey were invited to participate. They comepleted the modified OCC Survey, which focused on telehealth during the pandemic. Linear and logistic regression analyses were used to identify patient characteristics that influenced telehealth experiences and preferences for future telehealth use. Results: Perceived ease of participation in telehealth is a significant predictor of the change in patients’ ratings of their telehealth experience. We found that cancer patients had lower preferences for using telehealth in the future if they were older, female, or non-white; resided in an urban area; had no previous telehealth experience; had lower education; and had poorer mental health. Conclusions: To optimize cancer care and improve equitable access to high-quality telehealth care during the pandemic and beyond, clinicians and policymakers will need to consider patients’ self-reported experiences and their personal characteristics.

Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study.

The COVID-19 pandemic forced rapid adoption of telemedicine (TM) for breast oncology visits in the United States, but the appropriate role of postpandemic TM is uncertain. We sought to understand physician and advance practice practitioner perspectives on the use of TM for outpatient breast cancer care through an electronically administered survey. Breast medical oncology clinicians at two academic cancer centers and five satellite locations affiliated with the Dana Farber Cancer Institute and the Massachusetts General Cancer Center were invited to respond to a 21-question survey administered in September 2021 about clinicians' perceptions and attitudes toward TM during the previous 12 months. Of the 71 survey invitations, 51 clinicians (36 physicians and 15 advance practice practitioners) provided survey responses (response rate = 72%). Ninety-two percent of respondents (n = 47) agreed that TM visits enhance patient care. Ninety-two percent of respondents (n = 46) also agreed that TM is valuable for early-stage breast cancer follow-up visits. Most respondents felt that there was no difference between TM and face-to-face (F2F) visits when it came to patient adherence, ease of ordering tests, ease of accessing patient records, and workflow outside of the visit (82%, 82%, 78%, and 53%, respectively). Fifty-one percent of respondents (n = 26) said that TM was better for timely access to follow-up appointments. Most respondents said that F2F visits were better for seeing physical problems, personal connection with patients, overall quality of visits, and patient-physician communication (100%, 75%, 65%, and 63%, respectively). Breast clinicians believe that TM is a valuable tool to enhance outpatient breast cancer care. TM was felt to be appropriate for routine follow-up visits and second opinion consultations and is as good as or better than F2F visits for several routine aspects of breast cancer care.

Preventing clinical deterioration in cancer outpatients: Human centered design of a predictive model and response system.

e13567 Background: Patients (pts) with cancer in the outpatient setting are at a high-risk for adverse events, such as unplanned hospitalizations and ER visits. A recent study found that up to 30% of hospital admissions were preventable. Identifying pts at risk of avoidable clinical deterioration remains a challenge, as clinicians may not be aware of pts’ experiences at home. The growing use of health IT presents an opportunity to identify and respond to clinical deterioration in patients before an adverse event occurs. In this study, we describe a human-centered design (HCD) process used to develop a clinical deterioration risk prediction system to improve the detection of and response to deterioration in cancer outpatients. Methods: Predictive model: We enrolled eligible cancer pts and collected data from each one including: FitBit, geolocation, EHR, and weekly patient-reported outcome measures (PROMs). Pts and their family caregivers could also report non-routine events (NREs), defined as any deviation from expected optimal care. We also captured unplanned treatment events (UTEs), a clinically meaningful change in the pt’s treatment course or care pathway. We developed a predictive model that generates a pt’s 7-day risk of clinical deterioration. Response system: We are developing a risk communication system (RCS) to communicate predicted risk scores to clinical teams. Using a HCD process, we first conducted 36 observations across 100 patient encounters to understand the environment of use. Next, we conducted 18 clinician interviews to define user needs. We have conducted 7 multi-disciplinary design sessions to iteratively develop prototypes of the RCS. We are currently conducting formative usability testing to assess the prototype and gather clinician feedback. Results: Predictive model: We have enrolled 36 cancer outpatients (24 head &amp; neck, 9 gastrointestinal, and 3 lung). Pts completed a total of 219 weekly PROM surveys, reported 107 NREs and experienced 18 UTEs (e.g., infection). So far, models using EHR and PROM data are the most sensitive and precise (AUC: 0.983; 0.999). More patient data are required to develop higher quality stable models. Response system: We identified key design elements to include in the RCS, such as the caregiver’s phone number and the pt’s weight over time. Preliminary findings demonstrate high usability of the prototype RCS. Oncologists identified opportunities for the system to better support team communication and coordination, and to improve the identification and response to clinical deterioration in cancer outpatients. Conclusions: We have developed and tested a clinical deterioration risk prediction system for cancer outpatients. Future studies will implement the response system and evaluate its impact on clinical care.

Assessment of efficacy and validity of Khorana risk assessment model in cancer outpatients at a regional cancer center.

e18689 Background: Malignancy is a known risk factor for venous thromboembolism (VTE). Several risk assessment models have been proposed in the literature. Khorana score (KS) is by far the most favored VTE risk assessment tool in cancer outpatients. The KS incorporates the site of primary cancer, baseline hemoglobin, platelets, white blood cell count, and body mass index into the risk score. Patients are classified into low (KS = 0), intermediate (KS = 1-2) and high (KS≥ 3) risk groups. Low dose prophylactic anticoagulation for up to 6 months is recommended in patients with a KS of 2 or higher. In this study we attempted to validate the efficacy of Khorana risk model in our cancer population. Methods: We identified 270 patients (18 years and older) in 2018 and 2019 from our cancer registry with a new cancer diagnosis who received chemotherapy. All the components of KS including patient’s white blood cell count (WBC), hemoglobin, platelet count, baseline body mass index (BMI), and site of the primary were collected. We reviewed medical records to assess for development of VTE over time following initial cancer diagnosis. To assess the performance of Khorana score in our population, we utilized logistic regression and receiver operating characteristic curve (ROC) analysis. We further evaluated VTE free survival by Khorana score using Cox regression analysis. Results: Among 270 patients, the mean age was 60.4 (SD 14.0). 50.6 % were males (n = 136) and 49.6 % were females (n = 134). The most common cancer site was breast (n = 57) followed by prostate (n = 55), pancreas (n = 24), lymphoma (n = 22), bladder (n = 17), lung (n = 13), colon (n = 11), and acute myeloid leukemia (n = 6). The mean Khorana score was 1.2 (SD 1.1). Prophylactic anticoagulation was indicated in 84 patients (KS ≥ 2) but only 4 patients received prophylactic anticoagulation (1.4%). Using a KS cutoff score of 2 or more, the sensitivity was 55.6% (95% CI 0.31 to 0.78), specificity was 70.6% (95% CI 0.64 to 0.76) with a positive predictive value of 11.9% (95% CI 0.06 to 0.21) and negative predictive value of 95.7% (95% CI 0.91 to 0.98). The area under the ROC curve was 0.66, indicating poor performance of the KS. Using Cox regression, those with a KS of 3 or more were 6.3 times (95% CI 1.7 to 23.5) more likely to develop a VTE compared to those with a KS of zero. However, those with KS of 1 (RH 0.96; 95% CI 0.23 to 3.9) or KS of 2 (RH 1.3; 95% CI 0.28 to 6.1) were no more likely to develop a VTE compared to those with a KS of zero. Conclusions: In our patient population, patients were unlikely to receive prophylactic anticoagulation for VTE despite many meeting KS criteria. Using a KS of 2 or higher did not perform well in predicting the risk of a symptomatic VTE. Some VTE diagnoses may have been missed since only those with suspicion of VTE underwent diagnostic testing, which could influence KS performance. However, routine testing for VTE without symptoms or signs is not considered stand or care.